Scroll

daclatasvir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antivirals, hepatitis C Virus (HCV) NS5A inhibitors	4875	1009119-64-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: daclatasvir daclatasvir dihydrochloride daclatasvir hydrochloride daklinza BMS-790052-05 BMS-790052 daclatasvir HCl daclatasivr	an HCV NS5A inhibitor Molecular weight: 738.89 Formula: C40H50N8O6 CLOGP: 4.72 LIPINSKI: 2 HAC: 14 HDO: 4 TPSA: 174.64 ALOGS: -4.94 ROTB: 13 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

daclatasvir
daclatasvir dihydrochloride
daclatasvir hydrochloride
daklinza
BMS-790052-05
BMS-790052
daclatasvir HCl
daclatasivr

an HCV NS5A inhibitor

Molecular weight: 738.89
Formula: C40H50N8O6
CLOGP: 4.72
LIPINSKI: 2
HAC: 14
HDO: 4
TPSA: 174.64
ALOGS: -4.94
ROTB: 13

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ
Vd (Volume of distribution)	0.67 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	13.50 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	700 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
June 27, 2014	EMA
July 24, 2015	FDA	BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular carcinoma	327.46	30.34	62	3331	2132	63483497
Hepatitis C	199.22	30.34	48	3345	5226	63480403
Genotype drug resistance test positive	135.84	30.34	23	3370	410	63485219
Ascites	128.47	30.34	56	3337	40672	63444957
Hepatic encephalopathy	107.92	30.34	35	3358	11247	63474382
Hepatic failure	83.89	30.34	40	3353	35616	63450013
Fatigue	70.49	30.34	149	3244	887879	62597750
Headache	64.29	30.34	118	3275	633123	62852506
Oesophageal varices haemorrhage	61.11	30.34	14	3379	1220	63484409
Hepatic cirrhosis	58.92	30.34	28	3365	24706	63460923
Liver transplant	57.28	30.34	15	3378	2276	63483353
Hepatitis B reactivation	48.15	30.34	14	3379	3123	63482506
Viral mutation identified	45.97	30.34	12	3381	1798	63483831
Virologic failure	45.63	30.34	12	3381	1850	63483779
Renal impairment	44.05	30.34	37	3356	88318	63397311
Jaundice	40.47	30.34	23	3370	29228	63456401
Drug interaction	32.80	30.34	50	3343	229081	63256548
Treatment failure	32.18	30.34	46	3347	198997	63286632
Pulmonary arterial hypertension	31.90	30.34	18	3375	22559	63463070
Drug resistance	31.63	30.34	18	3375	22915	63462714

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular carcinoma	988.48	24.78	234	5780	7275	34943642
Hepatitis C	692.81	24.78	186	5828	9644	34941273
Genotype drug resistance test positive	683.12	24.78	125	5889	1020	34949897
Treatment failure	486.79	24.78	210	5804	46487	34904430
Liver transplant	211.75	24.78	55	5959	2479	34948438
Viral mutation identified	148.50	24.78	43	5971	2911	34948006
Hepatic encephalopathy	139.24	24.78	62	5952	14623	34936294
Drug ineffective	112.21	24.78	243	5771	456508	34494409
Hepatic cirrhosis	105.66	24.78	54	5960	17260	34933657
Fatigue	104.66	24.78	209	5805	370444	34580473
Virologic failure	104.03	24.78	34	5980	3446	34947471
Ascites	103.38	24.78	76	5938	46495	34904422
Headache	100.12	24.78	146	5868	200489	34750428
Hepatic failure	84.94	24.78	60	5954	34471	34916446
Therapeutic embolisation	74.78	24.78	16	5998	305	34950612
Hepatic cancer	72.24	24.78	33	5981	8242	34942675
Hyperbilirubinaemia	68.01	24.78	40	5974	16803	34934114
Hepatitis B reactivation	59.06	24.78	23	5991	3868	34947049
Insomnia	56.58	24.78	79	5935	103828	34847089
Genital herpes simplex	51.14	24.78	10	6004	119	34950798
Biliary colic	46.94	24.78	14	6000	1048	34949869
Varices oesophageal	45.92	24.78	19	5995	3736	34947181
Hepatitis C RNA increased	42.89	24.78	10	6004	285	34950632
Oesophageal varices haemorrhage	42.17	24.78	17	5997	3129	34947788
Genital herpes	39.85	24.78	11	6003	624	34950293
Abdominal cavity drainage	39.50	24.78	10	6004	405	34950512
Hepatorenal syndrome	37.79	24.78	15	5999	2651	34948266
Hepatitis C RNA positive	36.56	24.78	8	6006	170	34950747
Jaundice	35.42	24.78	35	5979	31847	34919070
Peritonitis bacterial	31.39	24.78	17	5997	6093	34944824
Embolism	30.04	24.78	18	5996	7811	34943106
Hepatic neoplasm	27.59	24.78	11	6003	1966	34948951
Transcatheter arterial chemoembolisation	27.01	24.78	4	6010	6	34950911
Liver disorder	25.67	24.78	30	5984	32967	34917950

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular carcinoma	1194.09	24.67	259	8280	8762	79727087
Hepatitis C	768.89	24.67	191	8348	11734	79724115
Genotype drug resistance test positive	571.00	24.67	102	8437	1206	79734643
Hepatic encephalopathy	243.18	24.67	93	8446	24073	79711776
Liver transplant	240.92	24.67	62	8477	4361	79731488
Treatment failure	237.99	24.67	174	8365	170312	79565537
Ascites	215.15	24.67	121	8418	75441	79660408
Viral mutation identified	200.00	24.67	52	8487	3806	79732043
Fatigue	147.82	24.67	313	8226	929414	78806435
Hepatic failure	137.16	24.67	84	8455	61128	79674721
Headache	122.44	24.67	236	8303	653536	79082313
Hepatic cirrhosis	121.74	24.67	64	8475	34842	79701007
Virologic failure	118.00	24.67	35	8504	4156	79731693
Hyperbilirubinaemia	97.16	24.67	49	8490	24469	79711380
Therapeutic embolisation	92.53	24.67	19	8520	484	79735365
Hepatitis B reactivation	89.32	24.67	31	8508	6077	79729772
Hepatic cancer	86.43	24.67	35	8504	10494	79725355
Oesophageal varices haemorrhage	75.73	24.67	25	8514	4211	79731638
Hepatitis C RNA increased	72.35	24.67	15	8524	401	79735448
Varices oesophageal	70.93	24.67	26	8513	5965	79729884
Insomnia	67.17	24.67	105	8434	245065	79490784
Renal impairment	61.53	24.67	80	8459	157703	79578146
Jaundice	57.86	24.67	47	8492	53302	79682547
Abdominal cavity drainage	51.91	24.67	13	8526	817	79735032
Hepatorenal syndrome	48.68	24.67	18	8521	4231	79731618
Drug ineffective	47.30	24.67	234	8305	1080679	78655170
Hepatitis B DNA increased	47.18	24.67	12	8527	803	79735046
Portal hypertensive gastropathy	45.05	24.67	13	8526	1401	79734448
Genital herpes simplex	45.01	24.67	10	8529	373	79735476
Hepatectomy	39.37	24.67	8	8531	193	79735656
Liver disorder	38.48	24.67	43	8496	72374	79663475
Peritonitis bacterial	37.53	24.67	19	8520	9548	79726301
Biliary colic	35.39	24.67	14	8525	3948	79731901
Anaemia	32.48	24.67	113	8426	444902	79290947
Genital herpes	32.11	24.67	11	8528	2073	79733776
Hepatitis C RNA positive	31.91	24.67	7	8532	246	79735603
Hydrocholecystis	31.60	24.67	8	8531	525	79735324
Liver transplant rejection	30.85	24.67	12	8527	3236	79732613
Hepatic neoplasm	30.23	24.67	12	8527	3414	79732435
Acute leukaemia	30.10	24.67	10	8529	1716	79734133
Mesenteric vein thrombosis	29.54	24.67	10	8529	1817	79734032
Embolism	28.28	24.67	18	8521	13964	79721885
Incorrect product administration duration	28.17	24.67	17	8522	12005	79723844
Renal disorder	27.68	24.67	28	8511	42077	79693772
Toxicity to various agents	27.12	24.67	6	8533	421534	79314315
Pulmonary arterial hypertension	26.62	24.67	23	8516	28343	79707506
Drug interaction	26.53	24.67	101	8438	415082	79320767
Transcatheter arterial chemoembolisation	26.13	24.67	4	8535	16	79735833
Fibrosis	25.17	24.67	12	8527	5297	79730552

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AP07	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections
ATC	J05AP58	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190107	Organic Anion Transporting Polypeptide 1B1 Inhibitors
FDA MoA	N0000190108	Organic Anion Transporting Polypeptide 1B3 Inhibitors
FDA MoA	N0000190113	Breast Cancer Resistance Protein Inhibitors
FDA EPC	N0000191256	Hepatitis C Virus NS5A Inhibitor
CHEBI has role	CHEBI:36044	antiviral drugs
CHEBI has role	CHEBI:83799	nonstructural protein 5A inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic hepatitis C	indication	128302006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.05	acidic
pKa2	12.44	acidic
pKa3	12.88	acidic
pKa4	13.27	acidic
pKa5	6.51	Basic
pKa6	5.91	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 30MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	8900566	Aug. 8, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 30MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	8900566	Aug. 8, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 30MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	9421192	Aug. 8, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 30MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	9421192	Aug. 8, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 60MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	8900566	Aug. 8, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 60MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	8900566	Aug. 8, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 60MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	9421192	Aug. 8, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 60MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	9421192	Aug. 8, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 90MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	April 13, 2016	DISCN	TABLET	ORAL	9421192	Aug. 8, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 90MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	April 13, 2016	DISCN	TABLET	ORAL	9421192	Aug. 8, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 30MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	8642025	Aug. 11, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 30MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	8642025	Aug. 11, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 60MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	8642025	Aug. 11, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 60MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	8642025	Aug. 11, 2027	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
EQ 30MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	8629171	June 13, 2031	METHOD OF INHIBITING HEPATITIS C VIRUS
EQ 60MG BASE	DAKLINZA	BRISTOL-MYERS SQUIBB	N206843	July 24, 2015	DISCN	TABLET	ORAL	8629171	June 13, 2031	METHOD OF INHIBITING HEPATITIS C VIRUS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	4.53	CHEMBL
Genome polyprotein	Polyprotein		POLG_HCVBK	INHIBITOR	EC50	11.05	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Genome polyprotein	Polyprotein		POLG_HCVH	INHIBITOR	EC50	10.30	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Nonstructural protein 5A	Unclassified		Q5L478_9HEPC		IC50	10.64	CHEMBL

External reference:

ID	Source
D10065	KEGG_DRUG
4034682	VUID
N0000191739	NUI
4034682	VANDF
CHEBI:83800	CHEBI
CHEMBL2023898	ChEMBL_ID
C549273	MESH_SUPPLEMENTAL_RECORD_UI
11266	IUPHAR_LIGAND_ID
1009119-65-6	SECONDARY_CAS_RN
DB09102	DRUGBANK_ID
1606217	RXNORM
229788	MMSL
30519	MMSL
d08285	MMSL
015679	NDDF
1172356004	SNOMEDCT_US
712519008	SNOMEDCT_US
714014007	SNOMEDCT_US
C3252090	UMLSCUI
CHEMBL2303621	ChEMBL_ID
9483	INN_ID
25154714	PUBCHEM_CID
LI2427F9CI	UNII

Pharmaceutical products:

None